Erectile dysfunction, or impotence as it is often called, is a condition where a man is unable to achieve and maintain an erection. The cause of the disorder may be psychological or physical. For some people being diagnosed with a sexual transmitted infection perhaps after using a Home StI Kits London company like bexley sexual health can cause temporary erectile dysfunction due to the anxiety and concern of having contracted the infection. But whatever the origin, finding an appropriate solution is usually high on the list of the patient’s priorities.
Impotence – The secret disorder
Even though 50% of men aged between 40 and 70 years of age will experience some level of erectile dysfunction, there is still a lot of secrecy and embarrassment surrounding the subject. However, a new gel developed by British pharmaceutical company, Futura Medical, has shown positive results in clinical trials.
A more spontaneous solution
Tackling the most common challenge faced by many a pharmaceutical services provider, when trying to find effective erectile dysfunction treatments, the new gel, Eroxon takes effect much more quickly than the current most popular treatment, Viagra.
Research by pharmaceutical consulting firms has found that the main problem with existing medication (including viagra) currently on the market is that they need to be taken in advance, meaning that a level of planning and foresight in required and conversely, that spontaneity is not an option. With Eroxon, results are seen as quickly as ten minutes after application, and if Futura’s product roadmap plans go ahead, there will soon also be a gel infused condom, which will help maintain erections.
Hope for ED sufferers in the UK
Although the gel is not available in the UK at present, it may not be long before it is offered on the NHS. Already, ED sufferers in Holland can purchase the product under the brand name Blue Diamond and, according to Futura’s CEO, James Barder, it is very safe for use by patients with mild impotence problems. There is also good news for angina sufferers, as there are no known contraindications with medications used to treat the condition, as is the case with Viagra.
The size of the global market for erectile dysfunction solutions currently stands at around $5bn, and the market leader Viagra accounts for over a third of this figure. If Eroxon gains approval in both the US and the UK, as is widely expected, this newcomer to the market could very well surpass these figures in the not too distant future.